Treatment of non-systemic Sjögren's syndrome: Potential prevention of systematization with immunosuppressant agent/biotherapy

IF 4.7 Q2 IMMUNOLOGY
Aude Belbézier , Thi Thu Thuy Nguyen , Mélanie Arnaud , Bruna Ducotterd , Marie Vangout , Alban Deroux , Catherine Mansard , Françoise Sarrot-Reynauld , Laurence Bouillet
{"title":"Treatment of non-systemic Sjögren's syndrome: Potential prevention of systematization with immunosuppressant agent/biotherapy","authors":"Aude Belbézier ,&nbsp;Thi Thu Thuy Nguyen ,&nbsp;Mélanie Arnaud ,&nbsp;Bruna Ducotterd ,&nbsp;Marie Vangout ,&nbsp;Alban Deroux ,&nbsp;Catherine Mansard ,&nbsp;Françoise Sarrot-Reynauld ,&nbsp;Laurence Bouillet","doi":"10.1016/j.jtauto.2024.100238","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Sjögren's syndrome (SS) is a systemic autoimmune pathology manifested mainly by a dry syndrome, intense asthenia and arthromyalgia. Systemic manifestations may also occur. Since 2019, immunosuppressant agents (IS) or biotherapies are recommended only for patients with systemic involvement. However, before 2019, in some cases, paucisymptomatic patients had been treated with IS/biotherapies, often off-label. <strong>Objective</strong>: We propose to evaluate the benefit and safety of using IS/biotherapy in patients with SS without systemic involvement. <strong>Methods:</strong> We retrospectively collected the clinical records of all patients with SS diagnosed according to ACR/EULAR diagnostic criteria followed up between January 1980 and October 2023 at Grenoble University Hospital (France). <strong>Results:</strong> Eighty-three patients were included: 64 with an initially non-systemic form. Of these patients with an initially non-systemic form, 24 were treated with IS/biotherapy. None of them developed secondary systematization, whereas 11 out of 40 patients in the untreated group did (p &lt; 0.05). On the other hand, IS/biotherapy did not appear to improve dry syndrome. There were no serious adverse events. <strong>Conclusion:</strong> Early introduction of an IS/biotherapy treatment appears to provide a benefit for the patient without side effects.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"8 ","pages":"Article 100238"},"PeriodicalIF":4.7000,"publicationDate":"2024-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S258990902400008X/pdfft?md5=2941ee00a1b6c48966a06947f00da1c8&pid=1-s2.0-S258990902400008X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Translational Autoimmunity","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S258990902400008X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Sjögren's syndrome (SS) is a systemic autoimmune pathology manifested mainly by a dry syndrome, intense asthenia and arthromyalgia. Systemic manifestations may also occur. Since 2019, immunosuppressant agents (IS) or biotherapies are recommended only for patients with systemic involvement. However, before 2019, in some cases, paucisymptomatic patients had been treated with IS/biotherapies, often off-label. Objective: We propose to evaluate the benefit and safety of using IS/biotherapy in patients with SS without systemic involvement. Methods: We retrospectively collected the clinical records of all patients with SS diagnosed according to ACR/EULAR diagnostic criteria followed up between January 1980 and October 2023 at Grenoble University Hospital (France). Results: Eighty-three patients were included: 64 with an initially non-systemic form. Of these patients with an initially non-systemic form, 24 were treated with IS/biotherapy. None of them developed secondary systematization, whereas 11 out of 40 patients in the untreated group did (p < 0.05). On the other hand, IS/biotherapy did not appear to improve dry syndrome. There were no serious adverse events. Conclusion: Early introduction of an IS/biotherapy treatment appears to provide a benefit for the patient without side effects.

非系统性斯约格伦综合征的治疗:使用免疫抑制剂/生物疗法预防系统化的可能性
背景舍格伦综合征(SS)是一种全身性自身免疫性病变,主要表现为干燥综合征、剧烈气喘和关节肌痛。也可能出现全身表现。自2019年起,只有全身受累的患者才建议使用免疫抑制剂(IS)或生物疗法。然而,在 2019 年之前,在一些病例中,无症状的患者曾接受过免疫抑制剂/生物疗法治疗,而且往往是非标治疗。我们的目标我们建议对无全身受累的 SS 患者使用 IS/ 生物疗法的益处和安全性进行评估。方法我们回顾性地收集了格勒诺布尔大学医院(法国)1980 年 1 月至 2023 年 10 月期间根据 ACR/EULAR 诊断标准确诊的所有 SS 患者的临床记录。结果:共纳入 83 名患者:64例最初为非系统性。在这些最初为非系统型的患者中,有24人接受了IS/生物疗法治疗。他们中没有人出现继发性系统化,而未治疗组的 40 名患者中有 11 人出现了继发性系统化(p < 0.05)。另一方面,IS/生物疗法似乎没有改善干燥综合征。没有出现严重的不良反应。结论早期采用IS/生物疗法治疗似乎能为患者带来益处,且无副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Translational Autoimmunity
Journal of Translational Autoimmunity Medicine-Immunology and Allergy
CiteScore
7.80
自引率
2.60%
发文量
33
审稿时长
55 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信